COPD Inhaler Devices

Common inhalers for chronic obstructive pulmonary disease 

Inhalers for chronic obstructive pulmonary disease are devices which deliver medicine to prevent and control symptoms and help reduce exacerbations - also known as lung attacks or flare ups. The variations between different inhaler devices can sometimes be confusing, but understanding them will help you make an informed choice about your care.

Inhalers are generally classified as:

  • 1. pressurized metered-dose inhalers (pMDIs)
  • 2. breath-actuated metered dose inhalers (bMDIs)
  • 3. dry powder inhalers (DPIs, single or multidose)
  • soft mist inhalers  

Inhalers can contain either a single medication or a combination of medications. An inhaler can deliver:

  • a bronchodilator, which helps to open up your airways and increase air flow
  • a corticosteroid, which helps to reduce inflammation in your airways
  • a combination of different bronchodilators
  • a combination of bronchodilator and corticosteroid

Which choice of inhaler is best for you?

The choice of inhaler device depends on a number of considerations. The type of inhaler or other device you use will depend on the medicine you are taking and your ability to use the device properly, as well as your own personal preferences. Consult with your healthcare professional about the different types of inhalers available to ensure that you get the most benefit from your inhaled medicines.


News, Resources and Education

Scientific Literature

Inhaler Devices for Chronic Obstructive Pulmonary Disease


Background: The choice of inhaler device for patients with chronic obstructive pulmonary disease (COPD) depends upon multiple attributes. An online survey was devised to assess COPD patients' and healthcare practitioners' (HCPs; physicians and nurses) opinions and preferences for inhaler devices.

Methods: Patients diagnosed with COPD ≥6 months from United States (US), United Kingdom (UK), France, and Germany, and HCPs from the US, UK, France, Italy, and Japan were enrolled to participate in an online quantitative 35 minutes survey. A proprietary analytical tool from Sawtooth Software was used to collect, randomize, and analyze participant opinions and preferences of device attributes, including functionality.

Results: A total of 245 patients (mean age, 60.7 years) completed the survey. Of these, 124 and 121 patients were taking fluticasone/salmeterol, and tiotropium, respectively. Patients cited ease of use, dose recording, and dose capacity (single or multi-dose) as important attributes for the device. Key factors that patients considered would make the device easier to use were fewer steps to operate the inhaler, confirmation that the dose has been taken correctly, easier coordination of breathing maneuver, and least resistance while inhaling. A total of 504 HCPs (380 physicians and 124 nurses) completed the survey, and cited patient satisfaction and ease of use as the most important attributes when selecting an inhaler device for patients. Dose recording and multi-dose versus single-dose designs were given less importance than other attributes such as patient satisfaction and cost by HCPs.

Conclusion: The survey provides important insights into what patients and HCPs consider to be key attributes of an ideal inhaler device for COPD management. Given that patients with COPD self-administer their COPD chronic medication and need to deliver the correct dose, it is important to consider these insights for the appropriate management of COPD.

Key words: : chronic obstructive pulmonary disease, healthcare practitioners' preference, inhaler devices, patient preference

J Aerosol Med Pulm Drug Deliv. 2015 Jun 1; 28(3): 219–228. doi: [10.1089/jamp.2014.1142]

PMCID: PMC4559157 PMID: 25265316


Chronic Obstructive Pulmonary Disease (COPD) is a complex disease with increasing morbidity and mortality. It is estimated that by year 2020, COPD will be the third leading cause of mortality worldwide. COPD represents a significant societal and economic burden throughout the world. Current strategy for the management of COPD recommends the use of inhaled medication for relieving symptoms and preventing complications and exacerbations.

Despite advancement in medical treatment, poor adherence remains a major challenge in the management of COPD, and adversely impacts health outcomes, quality of life, and healthcare expenditures.Between 40% and 60% of patients with COPD do not adhere to the prescribed regimen. Factors impacting adherence in COPD may be associated with patients (health beliefs, cognitive ability, co-morbidities, and psychological condition), drug treatment (method of drug administration, dosing regimen, polypharmacy, and side effects), and societal factors (access to medication, social support, device training, and follow-up).

Efficient delivery of inhaled medication is essential for the success of COPD therapy. The inhaler device may contribute to optimal drug deliveryand also impact patient adherence. A wide range of inhaler devices are available, including pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulizers, and soft mist inhalers (SMI). Each type of device has its own advantages and disadvantages.

When considered independently of drug class, choice of inhaler device depends on availability and cost of inhalation treatment, clinical setting, age of the patient, dosing regimen, physician and patient preference, and ability of the patient to use the inhaler. Patient satisfaction, and consequently adherence, largely depend on the patients' attitude towards the inhaler and their ability to use the device. However, studies have shown that patients often struggle with various attributes of different inhalers, and poor technique is common regardless of the device used.

It is important to understand which device attributes may influence physicians' and patients' preference towards COPD therapy and drive adherence. Here, we present the results of a device choice survey, which aimed to assess the opinions and preferences of patients and healthcare practitioners (HCPs; physicians and nurses) for inhaler devices.

Materials and Methods


The survey was conducted by P\S\L Research Europe in COPD patients and HCPs (physicians, both general practitioners and pulmonologists; and nurses). Patients aged ≥40 years who had been diagnosed with COPD for ≥6 months participated from the United States (US), the United Kingdom (UK), France, and Germany. Physicians who participated were from the US, UK, France, Italy, and Japan. They had been practicing for 3–34 years, treating 40–100 patients per month, had spent 20%–75% time treating patients, and had personally trained at least one COPD/asthma patient per month on inhaler technique. Nurses in the survey were from the US and UK. They were responsible for the management of COPD/asthma patients, had been involved in the education and training of COPD/asthma patients for 3–34 years, and had trained at least one patient per month.


Online quantitative surveys of around 35 minutes were completed by patients with COPD and asthma (March 31–April 30, 2010) and HCPs (January 5–29, 2010). Initial data were reported at European Respiratory Society (ERS) congress in 2011, and this article presents further more detailed analysis from COPD patients. The patient questionnaire was divided into four sections: (1) patients' current situation including specialization of the consulting physician, frequency of visits to physician, severity of the disease, etc.; (2) conjoint analysis exercise, which narrowed down the patients' preference for eight attributes of an ideal inhaler (see below), measured the relative importance of each attribute, and analyzed the attributes with number of doses per day, an attribute driven by drug, separately; (3) patient preferences, which identified the most important and difficult attributes of current inhaler, patients' situation, and inhaler attributes on a scale of 17; and (4) demographic questions.

The HCP questionnaire covered both COPD- and asthma-related questions (approximately 50% each). In this article, we present results from the completed COPD questions. The HCP questionnaire was divided into four sections: (1) prescribing/practice behavior; (2) conjoint analysis exercise that narrowed down HCPs' preference for 11 attributes (see below) of an ideal inhaler, measuring the relative importance of each attribute, and analyzing the attributes with total cost and treatment class separately; (3) other priorities, such as ranking of attributes that are important for ease of use; and (4) demographic questions.

Attributes evaluated in patients included doses carried, ease of use, dose confirmation, dose recording, size of inhaler, technology, whether disposable or recyclable, and ready to inhale cue. Number of doses per day (although driven by drug, rather than device) was also included in the evaluation. Attributes evaluated in HCPs were type of inhaler and doses carried, screening requirements, patient feedback, ease of use and training, dose confirmation, dose recording, size of inhaler, compliance evidence, efficient delivery to the lung, technology, disposable or recyclable device, cost and treatment class.


Sawtooth Software's adaptive choice-based conjoint analysis (ACBC)(17) and choice-based conjoint analysis (CBC) products were used to collect, randomize, and analyze responses about choice across various attributes and functions of inhalers. Attributes were analyzed individually for their importance. Each attribute was described by attribute level statements to which the respondent indicated their degree of agreement. For example, within the size of inhaler attribute, the attribute levels were (1) smallest size, (2) middle size, and (3) largest size. Based on individual responses, utility values for attributes levels, expressing positive or negative impact, were derived. The higher the utility value for a given attribute level, the more value this attribute level holds for respondents compared to the other levels of the same attribute. A positive utility value for an attribute level indicated that to be more desirable for a respondent than an attribute level with a negative utility value. For instance, a utility value of +100 was three times stronger than a utility value of −50.

Using the utility value for the individual attribute levels, the relative importance of an attribute was calculated. For each attribute, a larger spread from the highest to lowest utility values indicated a higher importance to respondents versus other attributes with comparatively narrow spread of utility values. Relative importance of overall device attributes versus compounding factors such as number of the doses per day, cost, and drug class was also calculated. Relative attribute importance scores were expressed as percentages. Data collection and analyses were not associated with, nor related to, any specific attribute of marketed brands or devices.

Characteristics of patient participants: A total of 245 COPD patients (US, 62; UK, 62; Germany, 59; France, 62) participated in the survey. Mean age of patients and duration of COPD was 60.7 years, and 8.3 years, respectively. The majority of patients had moderate-to-severe airflow limitation, with the most common symptoms being shortness of breath, chest tightness, and chronic cough. A total of 124 patients were taking fluticasone/salmeterol (Advair®), and 121 patients were taking tiotropium (Spiriva®) as a maintenance therapy. In patients taking fluticasone/salmeterol, a multi-dose DPI (mDPI) was most commonly used (53%), followed by a pMDI (40%) or both (7%). Patients taking tiotropium were using a single-dose DPI inhaler (93%), SMI (6%), or both (1%). Patients were under the care of a primary care physician (45%), specialist respiratory physician (pulmonologist; 41%), internal medicine specialist (9%) or other healthcare providers (5%).

Many HCPs felt that patient satisfaction and preference was more important than any other attribute of an inhaler device, with the main reason given for this being an association with improvement in adherence. HCPs felt the least acceptable attributes were patient dissatisfaction and subsequent request for an alternative, monthly disposal, and being hard to use/teach, as these increased inconvenience and reduced compliance. Conjoint results indicated that the device attributes account for 79%–85% of the relative importance versus cost (6%–10%) and treatment class (7%–11%;)

Patient opinions and preferences

Patients reported being satisfied with their current inhalers, giving a rating of 5.5 on a scale of 1–7. Overall, patients were certain that they had been taking the dose fully and correctly with a rating of 5.3 on a scale of 1–7. Approximately 37% patients (43% US and 35% Europe [34% UK; 33% Germany; and 38% France]) usually checked the dose counter (if present) every time they took their medication. Patients preferred to know that they had taken the right dose by either feeling the medication working in their lungs (36%) or by visual confirmation (31%). A total of 20% of patients gave priority to hearing confirmation that they had received a dose, and 13% rated feeling the dose by taste or sensation.

Requests for changing inhaler were infrequent. The most common reasons for changing the inhaler were that the medication was not working (48%) or that the previous device was not functioning (23%). A further 18% responded that their previous device was hard to use, 6% reported that previous inhaler was no longer available, and 5% provided other reasons for changing inhaler.

The three main inhaler attributes that the patients considered to be most important were ease of use/convenience, efficacy, and inhaler size which were given primary importance by 66%, 29%, and 27% patients, respectively. Patients stated that an inhaler with attributes such as least number of steps to operate, easier way to tell that the dose has been taken correctly, easier coordination of breathing in and out at the right times, and with least resistance when inhaling would make it easier to use. Patients rated these features with a score of 5.8, 5.7, 5.7, and 5.6, respectively, on a scale of 1–7.

Most adherent patients in COPD were older, with shortness of breath, taking a large number of medications for their conditions, and seek visual dose confirmation. Patients with severe COPD, who were taking most medications for their conditions, were mostly on Spiriva® HandiHaler, were somewhat satisfied, somewhat adherent, and least interested in ease of use features. In contrast, moderate COPD patients, who were mostly taking Spiriva® Handihaler, were most satisfied and most adherent. They were interested in easy-to-use features of the inhaler. Moderate-severe patients suffering from chronic bronchitis taking least medication were not dominated by any specific inhaler (an almost equal number of patients were on Spiriva® and Advair® [Diskus or pMDI]) and they were somewhat satisfied, and most adherent with Spiriva® Handihaler. These patients were highly interested in easy to use features.

HCP opinions and preferences

According to HCPs, the main reason for the patients changing their inhaler in the previous month, was patients' inability to use the device correctly (22.6% [8.4% patients failed to extract full dose; 6.4% patients did not understand operating steps, 5.6% patients had dexterity issues; 2.2% other issues]), followed by changes in medication (6.2%), inhaler being too cumbersome (4.2%), inhaler failure or breakage (1.8%), and other general dissatisfaction (3.0%). HCPs' ratings in order of importance for making a device easier to use were less steps to operate it, breath-actuation, and the least force required to operate it.

One of the considerations from HCPs was capturing/downloading of patient data for assisting/engaging noncompliant patients. HCPs believed that technology is most appealing when related to adherence. HCPs would prefer inhalers that capture data electronically to monitor compliance (30%–42%) and help patients engage with the management of COPD (16%–55%.


This survey was designed to assess patients' and HCPs' opinions and preferences for inhaler devices. It revealed ease of use as one of the most important device attributes for both patients and HCPs. This finding is in line with previous studies. Patient satisfaction and ease of use were the most important attribute for HCPs, and were the main reasons why HCPs selected an inhaler for their patients. The survey showed that HCPs favor devices that match patient preference and drive adherence. According to the HCPs, devices that were easy to use, and provided assurance to patients that they had taken the full dose correctly promoted patient adherence. In contrast, dose counter and multiple dosing versus single-dosing capability were considered less important than patient satisfaction, class, cost, etc. by HCPs. Since different attributes have been considered for patients and HCPs, a direct comparison is difficult.

Both patients and HCPs stated that breath actuation was an important attribute. It eliminated the requirement to coordinate breathing and activation maneuvers. Dry powder inhalers do not require this coordination, but due to their design, they are associated with some resistance to inhalation. Patients in this study stated that low resistance was an important attribute, which is consistent with a previous report that decreased resistance increased the acceptability of an inhaler.

In this study, HCPs stated that the most frequent reason for patients changing their inhaler in the previous month was inability to use the device correctly (22.6%) rather than change in medication (6.2%). Errors in handling the inhaler are common in patients with COPD. One study documented that nine out of 10 patients did not use their inhaler correctly, which impacted adherence and led to the suboptimal management of COPD. Moreover, the use of multiple inhalers needed for different medications in combination therapy (when disease progressed) confused the patients and further reduced compliance.

Patient-related issues, which impact adherence to medication, include inhaler preference or satisfaction level, co-morbidities and physical issues, cognitive and mood disorders, whereas physician-related issues include lack of awareness and knowledge on how to effectively instruct patients in proper inhaler use. Often, HCPs prescribe inhalers based on available/preferred drugs, without considering whether the patient can effectively use the device, potentially impacting adherence to the prescribed therapy.

HCPs believe that technology is most appealing for the purpose of aiding compliance and capturing/downloading of patient data is important for assisting/engaging noncompliant patients. However, technology features, which require additional training, are negatively perceived by HCPs. Technology should not decrease patient satisfaction or decrease HCP-perceived ease of use, or increase the level of patient training needs.

Overall, this survey highlights some of the key factors that determine patients' device preference and HCPs' perception of relevant attributes. Improved device selection based on individual patient requirements could help make COPD treatment more acceptable to patients leading to more successful COPD disease management.


In conclusion, this study demonstrated that for patients, ease of use is a key characteristic of the ideal inhaler device. For HCPs, patient satisfaction and ease of use were the most important attributes when selecting an inhaler device. According to patients, minimal steps to operate, breath-actuated mechanism, and confirmation of dose delivery, would make an inhaler easier to use. Dose recording and multi-dose versus single-dose designs were given less importance than other attributes such as patient satisfaction and cost by HCPs.

This study was published in PubMed, US National Library of Medicine. Original material by the Journal of Aerosol Medicine and Pulmonary Drug Delivery - Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare Practitioners  J Aerosol Med Pulm Drug Deliv. 2015 Jun 1; 28(3): 219–228. doi: [10.1089/jamp.2014.1142]  PMCID: PMC4559157 PMID: 25265316

© Copyright COPD Canada 2023 All rights reserved.

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.